Vaxigrip Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Trivalent influenza vaccine (split virion, inactivated)

Indications/Uses

Prevention of influenza disease caused by the 2 influenza A virus subtypes & the influenza B virus type contained in the vaccine for active immunisation of adults, including pregnant women, & childn ≥6 mth of age; & passive protection of infants from birth to <6 mth of age following vaccination of pregnant women.

Click to view Vaxigrip detailed prescribing information

Dosage/Direction for Use

IM/SC Adult & childn 6 mth to 17 yr One dose of 0.5 mL. Childn <9 yr (not previously vaccinated) Give a 2nd dose of 0.5 mL after an interval of at least 4 wk. Infant from birth to <6 mth Passive protection w/ one dose of 0.5 mL given to pregnant women.

Click to view Vaxigrip detailed prescribing information

Overdosage

View Vaxigrip overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to trivalent flu vaccine or to any component that may be present as traces eg, eggs (ovalbumin, chicken proteins), neomycin, formaldehyde & octoxinol-9.

Click to view Vaxigrip detailed prescribing information

Special Precautions

Should not be administered intravascularly. Caution in case of an anaphylactic reaction following administration. Postpone vaccination in patients w/ acute febrile illness until fever is resolved. Administer w/ caution to subjects w/ thrombocytopenia or bleeding disorder. Syncope can occur as psychogenic response to needle inj. Ab response in patients w/ endogenous or iatrogenic immunosuppression may be insufficient. May not protect all vaccinees. Not all infants <6 mth of age born to women vaccinated during pregnancy will be protected by passive protection. Safety & efficacy of active immunisation have not been established in infants <6 mth of age.

Click to view Vaxigrip detailed prescribing information

Use In Pregnancy & Lactation

Click to view Vaxigrip detailed prescribing information

Adverse Reactions

Inj site pain. Adult: Headache, myalgia, malaise. Elderly: Headache, myalgia. Adolescent & childn 9-17 yr: Myalgia, headache, malaise, shivering, inj site erythema, inj site swelling. Childn 3-8 yr: Malaise, inj site erythema, myalgia, headache, inj site swelling, inj site induration, shivering. Childn 24-35 mth: Inj site tenderness, fever, inj site erythema, malaise, myalgia, headache. Childn 6-23 mth: Inj site tenderness, fever, inj site erythema, irritability, abnormal crying, appetite lost, drowsiness, vomiting.

Click to view Vaxigrip detailed prescribing information

Drug Interactions

Use separate inj sites & separate syringes if given at the same time as other vaccines. Immunological response may be reduced if patient is undergoing immunosuppressant treatment.

Click to view Vaxigrip detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Vaxigrip detailed prescribing information

Storage

View Vaxigrip storage conditions for details to ensure optimal shelf-life.

Description

View Vaxigrip description for details of the chemical structure and excipients (inactive components).

Action

View Vaxigrip mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BB02 - influenza, inactivated, split virus or surface antigen ; Belongs to the class of influenza viral vaccines.

Regulatory Classification

P₁S₁S₃

Presentation/Packing

Form

Vaxigrip susp for inj (pre-filled syringe) 0.5 mL/dose

Packing/Price

1's

Vaxigrip

influenza vaccine

Manufacturer:

Sanofi

Distributor:

Zuellig